Mather Group LLC. Has $2.11 Million Holdings in Stryker Co. (NYSE:SYK)

Mather Group LLC. trimmed its holdings in shares of Stryker Co. (NYSE:SYK) by 1.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,860 shares of the medical technology company’s stock after selling 68 shares during the quarter. Mather Group LLC.’s holdings in Stryker were worth $2,110,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Dunhill Financial LLC grew its stake in Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares during the last quarter. Darwin Wealth Management LLC bought a new stake in Stryker during the third quarter valued at about $36,000. Crews Bank & Trust acquired a new stake in shares of Stryker in the fourth quarter valued at about $39,000. Hara Capital LLC bought a new position in shares of Stryker in the third quarter worth about $42,000. Finally, Grove Bank & Trust lifted its position in shares of Stryker by 84.8% during the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after purchasing an additional 56 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Up 0.4 %

SYK opened at $392.55 on Wednesday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The firm has a market cap of $149.65 billion, a price-to-earnings ratio of 50.59, a PEG ratio of 2.78 and a beta of 0.96. The firm’s 50-day simple moving average is $376.81 and its 200-day simple moving average is $363.64. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the business earned $3.46 earnings per share. Equities research analysts anticipate that Stryker Co. will post 13.5 EPS for the current fiscal year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st were given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date was Tuesday, December 31st. Stryker’s dividend payout ratio is presently 43.30%.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.50% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have commented on SYK shares. Truist Financial lifted their price target on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. The Goldman Sachs Group boosted their target price on shares of Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research report on Thursday, January 30th. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $370.00 to $445.00 in a report on Monday, December 2nd. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Finally, JPMorgan Chase & Co. lifted their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $419.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.